Please login to the form below
trastuzumab emtansine
This page shows the latest trastuzumab emtansine news and features for those working in and with pharma, biotech and healthcare.
NICE relents on Kadcyla after Roche pricing negotiations
The agreement comes after years of wrangling between NICE and the pharma group over the price of Kadcyla (ado-trastuzumab emtansine), which has a list price of £90, 000 a year ... older HER2-targeting drug Herceptin (trastuzumab) with capecitabine that
Latest news
-
A new decade of disruption: meeting the biosimilar challgenge
High price tags have seen a string of rejections for routine NHS use by the UK watchdog NICE, including cancer MAbs Avastin (bevacizumab), Kadcyla (ado-trastuzumab emtansine) and Perjeta (pertuzumab). ... An example can be seen in Roche’s introduction
-
Roche in "unprecedented" launch period for new medicines
The star in Roche's show was once again its trio of HER2-positive breast cancer drugs - Herceptin (trastuzumab), Perjeta (pertuzumab) and Kadcyla (trastuzumab emtansine) - whose sales increased 9% to
-
Roche's melanoma combo "too expensive" for NHS use, says NICE
NICE arrived at a similar conclusion when it published a review of breast cancer drugs Perjeta (pertuzumab) in May and Kadcyla (trastuzumab-emtansine) at the end of last year.
-
Immunotherapy and future directions in oncology
Monoclonal antibody-based technologies have now been in use for decades targeting specific cancer cells to serve either as therapeutics (eg Genentech's trastuzumab, Herceptin) or invitro diagnostics (immunoassays) or to ... Kadcyla (trastuzumab emtansine,
-
Roche says Tecentriq "off to a good start"
Strong gains for Perjeta (pertuzumab) and Kadcyla (ado-trastuzumab emtansine) reinforced a 5% increase for HER2 stalwart Herceptin (trastuzumab) to 3.4bn francs.
More from news
Approximately 5 fully matching, plus 49 partially matching documents found.
Latest Intelligence
-
An eye towards the biobetter in South Korea
It was noteworthy that the Celltrion's announcement happened to coincide with Roche's clinical data presentation of its Herceptin biobetter, Trastuzumab-emtansine (T-DM1). ... CT-P26. Celltrion. Trastuzumab-dolastatin 10 antibody drug conjugate. S Korea.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
-
Scientific Director
-
Great salary and bebefits
- Editorial Team Leader or Scientific Director
-
£50, 000 - £55, 000 benefits
-
Senior Medical Writer
-
Great salary and benefits
-
Senior Programme Executive
-
Salary TBC
-
Account Manager, Healthcare PR
-
£40, 000 – £42, 000 great benefits and bonuses
- Principal Medical Writer, Medical Communications, Relocate to Ca...
-
Excellent Salary
- FREELANCE Account Manager – Creative Healthcare Advertising – Lo...
-
SUPERB DAY RATES AVAILABLE
- FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...
-
EXCELLENT DAY RATES AVAILABLE
- Senior Account Manager / Account Director
-
Great salary and bebefits
- Head of Operations/ BUD, Healthcare PR, London – Excellent leade...
-
Excellent Package
- Senior Medical Writer, Medical Communications, Relocate to Cardi...
-
Excellent Salary
-
Senior Medical Writer
-
Great salary and bebefits
- Senior / Principal Regulatory Writer – Home Working - UK or US
-
HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS
- Account Manager – Med Comms – London
-
Salary TBC
- Senior Account Manager – Med Comms – Kent
-
Salary TBC
- Editor > Senior Editor – Medical Education – London
-
Very competitive with excellent benefits
Subscribe to our email news alerts
PMHub
M3 (EU)
M3 was founded in 2000 with the goal of changing the world of medicine through making full use of the...
Latest intelligence
- Pharma’s isolated islands of innovation
- With service design and technology often failing the patient, why perspective on improving outcomes need to change...
- Uncertainty, austerity and Brexit
- What does it mean for the life science sector?...
- The Holy Grail of HCP Access
- This is the data you need to gain access....
Quick links
Infographics
